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Abstract 
 
 
The most common cystic fibrosis (CF) mutation, ∆F508 in the nucleotide binding 
domain-1 (NBD1), impairs CFTR coupled-domain folding, plasma membrane (PM) 
expression, function and stability. VX-809, a promising investigational corrector of 
∆F508-CFTR misprocessing, has limited clinical benefit and incompletely understood 
mechanism, hampering drug development. Based on the effect of second site suppressor 
mutations, robust ∆F508-CFTR correction likely requires stabilization of NBD1 and the 
membrane spanning domains (MSDs)-NBD1 interface, both established primary 
conformational defects. Here, we elucidated the molecular targets of available 
correctors; class-I stabilizes the NBD1-MSD1/2 interface, class-II targets NBD2, and 
only chemical chaperones, surrogates of class-III correctors, stabilize the human ∆F508-
NBD1. While VX-809 can correct missense mutations primarily destabilizing the 
NBD1-MSD1/2 interface, functional PM expression of ∆F508-CFTR also requires 
compounds that counteract the NBD1 and NBD2 stability defects in CF bronchial 
epithelial cells and intestinal organoids. Thus, structure-guided corrector combination 
represents an effective approach for CF therapy. 
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Cystic fibrosis transmembrane conductance regulator (CFTR) is an ATP-binding 
cassette transporter and functions as a cAMP-dependent Cl- channel at the apical plasma 
membrane (PM) of epithelial cells1. CFTR comprises two membrane spanning domains 
(MSD1, MSD2) with four cytosolic loops (CL1-4), and three cytosolic domains: a 
regulatory (R) and two nucleotide-binding domains (NBD1, NBD2). CFTR domain 
swapped architecture forms multiple domain-domain interfaces that appear to be critical 
in the channel structural and functional integrity2-4 (Fig.1a). Newly synthesized CFTR is 
N-glycosylated and undergoes co-translational domain folding and post-translational, 
coupled-domain assembly in the ER2,5-9, aided by a network of molecular chaperones10,11 
(Supplementary Fig.1a). Upon bypassing the ER quality control checkpoints and 
traversing the Golgi complex, the native CFTR undergoes complex-glycosylation1,11. 
CF, one of the most common inherited disease in the Caucasian population, is 
caused by loss-of-function mutations of CFTR that lead to the imbalance of airway 
surface fluid homeostasis, mucus dehydration, hyperinflammation, bacterial 
colonization, and consequently recurrent lung infection, the primary cause of morbidity 
and mortality in CF1,12,13. Deletion of F508 (∆F508) in the NBD1, the most prevalent 
CFTR mutation present in ~90% of CF patients, causes global misfolding and ER 
associated degradation (ERAD) via the ubiquitin proteasome system, resulting in 
marginal PM expression of the partially functional ∆F508-CFTR1,6,11,14. The residual PM 
channel activity could be enhanced by modulating the ∆F508-CFTR biosynthetic 
processing, peripheral stability, and channel gating by low temperature, chemical 
chaperones or small molecules14-19. 
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While symptomatic therapies have increased the life expectancy of CF patients, 
considerable efforts have been devoted to identify compounds that can increase either 
the mutant biosynthetic processing efficiency and cell surface density (“correctors”) or 
the activity of PM resident mutant CFTR (“potentiators”)19. VX-770 (Ivacaftor), the 
only approved potentiator drug, substantially enhances the channel function of several 
mutants20, as opposed to available “correctors” that are modestly effective with 
incompletely understood mechanism14,17,21. In principle, correctors may facilitate ∆F508-
CFTR folding via direct binding as pharmacological chaperones (PC)22, or indirectly, as 
chemical chaperones (CC, e.g. glycerol, TMAO and myo-inositol)16,23. Correctors may 
also enhance the mutant functional expression as proteostasis regulators (PR)11 by 
modulating the cellular machineries responsible for folding, degradation, and vesicular 
trafficking of ∆F508-CFTR (e.g. 4-phenylbutyrate, HDAC inhibitor, HSF1-inducers and 
kinase inhibitors, see for review11,19). VX-809, the most promising investigational 
corrector, restores the mutant PM expression and function to <15% of WT-CFTR in 
immortalized and primary human bronchial epithelia14. Although circumstantial 
evidence suggests that VX-809, similarly to some of the previously identified correctors 
(e.g. C3 [VRT-325] and C4 [corr-4a]) and potentiators (e.g. P1 [VRT-532] and VX-
770), directly targets ∆F508-CFTR during ER biogenesis, the molecular basis of 
correction remains elusive14,24. While the VX-809-induced ∆F508-CFTR activity is 
potentiated by two fold with VX-770 at the PM in preclinical settings14, additional 
improvement seems to be required in corrector efficacy to achieve substantial clinical 
benefit in CF21.  
 Recent studies revealed that the ∆F508-NBD1 is thermodynamically and 
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kinetically destabilized at physiological temperature and suggested that NBD1 
stabilization would effectively counteract ∆F508-CFTR misprocessing25,26. Substantial 
stabilization of the ∆F508-NBD1 by suppressor mutations, however, resulted in a 
limited increase in folding and PM expression of the ∆F508-CFTR27,28. Remarkably, 
robust rescue (65-80%) of ∆F508-CFTR folding could be achieved by suppressor 
mutations that simultaneously stabilized the ∆F508-NBD1, as well as the NBD1 
interface with the CL4 coupling helix in the MSD227,28. These observations suggest that 
efficient correction of both primary structural defects is necessary and sufficient to 
restore ∆F508-CFTR function close to WT level in most CF patients. As a corollary, it is 
conceivably that correction of one of the primary (NBD1 or the NBD1-MSD2 interface) 
or a secondary structural defect (e.g. NBD2 misfolding5) accounts for the ∆F508-CFTR 
limited rescue efficiency by correctors identified to date11,14,17,19,21,22,29. Furthermore, 
combinations of correctors that counteract distinct conformational defects may 
potentiate each other effect on ∆F508-CFTR folding and function in analogy to 
suppressor mutations of the primary folding defects27,28 (Supplementary Fig.1b).  
 Based on in vitro studies of isolated ∆F508-NBD1 in combination with in vivo 
CFTR processing, functional assays, and in silico docking analysis, as well as published 
data22, here we propose that correctors can be mechanistically classified into three 
groups. We also show that the efficacy of VX-809, targeting the NBD1-MSD1/2 
interface, can be significantly potentiated with two other classes of chemicals, as 
determined by ∆F508-CFTR folding, PM expression, stability, and function in cell 
culture models and intestinal organoids from CF patients. Thus, targeting multiple 
conformational defects enables us to counteract ∆F508-CFTR misfolding, demonstrating 
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that structure-guided corrector combination may provide an effective therapeutic 
strategy in CF. 
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Result 
 
Class-I corrector plus NBD1 stabilization restore folding 
We postulated that small molecule combinations targeting both primary folding defects 
would achieve WT-like folding of ∆F508-CFTR as documented in case of second site 
suppressor mutations27,28. To categorize the available corrector molecules 
(Supplementary Results, Supplementary Table1) according to their preferential targets, 
we determined the rescue efficiency of ∆F508-CFTR containing either the genetically 
stabilized NBD1 (by R1S mutation: G550E, R553Q, R555K and F494N; second site 
mutations are defined in Supplementary Table 2) or the stabilized NBD1-MSD2 
interface (by the R1070W mutation in the CL4) (Fig.1a). We confirmed that the 
R1070W or R1S suppressor mutation modestly increased the ∆F508-CFTR PM density 
from <2 % to 7 or 16% of the WT level, respectively, determined by cell surface ELISA 
in BHK cells27 (Supplementary Fig.2a). VX-809, C18 (a VX-809 analogue) or C3, the 
most effective correctors in our screen, increased the PM density of ∆F508-CFTR-R1S 
and ∆F508-CFTR-R1070W to 93-100% and 30-34% of the WT, respectively (Fig.1b). 
This suggests that VX-809, C18 and C3 preferentially target the NBD1/MSD2 interface 
over the NBD1 energetic defect and they were designated as class-I correctors (Fig.1b 
and Supplementary Fig.2a). The preferential rescue of the NBD1-MSD2 interface and 
NBD1 stability defects was estimated by the augmented PM density of ∆F508-CFTR-
R1S (ResR1S) and ∆F508-CFTR-R1070W (ResR1070W), respectively, a measure that 
indicates the capacity of correctors to synergize with the respective suppressor mutation 
(Supplementary Fig.2a). The ratio of ResR1S over ResR1070W suggested that VX-809, C18 
or C3 has ~3.5 fold more stronger stabilizing effect on the NBD1-MSD2 interface than 
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on the NBD1 (Fig.1c). This inference was confirmed by using ∆F508-CFTR variants, 
containing functionally analogous 3S (F494N, Q637R, and F429S) and R (G550E, 
R553Q, R555K) or V510D suppressor mutations that stabilize the NBD1 or the NBD1-
MSD2 interface, respectively7,27,30,31. VX-809, C18 or C3 increased PM density of 
∆F508-CFTR-3S and ∆F508-CFTR-R from 7-25% to 60-120% of WT and their 
complex-glycosylation, but was less effective in case of ∆F508-CFTR-V510D similar to 
∆F508-CFTR-R1070W (Supplementary Fig.2b-c). A similar difference was obtained by 
analyzing the magnitude of fold-correction relative to that induced by the respective 
second-site mutation(s) alone. The reduced rescue efficiency of the ∆F508-CFTR-3S 
relative to ∆F508-CFTR-R1S by class-I correctors may be attributed to the more 
efficient stabilization of the NBD1-NBD2 interface with R1S suppressor mutation.  
Metabolic pulse-chase experiments confirmed that only combination of VX-809, 
C18 or C3 with NBD1 (R1S) but not with interface stabilization (R1070W or V510D) 
enhanced ∆F508-CFTR folding efficiency near to the WT level (22-32%), indicating a 
4-8-fold potentiation between class-I correctors and R1S mutation effect (Fig.1d and 
Supplementary Fig.2d). Dual acting compounds such as C15 (corr-2b32) and CoPo-22 
(CoPo33) combining corrector and potentiator effect only slightly enhanced the PM 
density of ∆F508-CFTR variants (Supplementary Fig.2a). 
The WT-like ∆F508-CFTR complex-glycosylation, function and PM density was 
reproduced by genetic stabilization of NBD1 and NBD1-MSD2 interface, as well as by 
the combination of class-I corrector and NBD1 suppressor mutations in polarized human 
immortalized CF bronchial respiratory epithelial (CFBE41o-) cells (Supplementary 
Fig.3).  Class-I correctors increased the PM density, complex-glycosylation and apical 
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Cl- current (ICl(apical)) of ∆F508-CFTR to ~100-130 % and ~30 % of the WT level in 
the presence of R1S and R1070W, respectively, in CFBE41o- cells expressing the 
mutant channel under the control of tetracycline responsive promoter (Fig.1e-f and 
Supplementary Fig.3e-g), consistent with preferential stabilization of the NBD1-MSD2 
interface by class-I correctors in CFBE41o- cells. 
To evaluate the efficiency of class-I corrector as a function of the ∆F508-NBD1 
conformational stability, the relationship between NBD1 stability (reflected by the Tm 
values of 0S, 1S [F494N], 3S or R4S suppressor mutant of ∆F508-NBD1 or WT-NBD1, 
listed in Supplementary Table2) and PM density of the respective CFTR variants was 
established. The WT-CFTR PM expression was dependent on the NBD1 stability at an 
8-fold steeper slope (12.9 ± 3.1 %/°C), as compared to that of ∆F508-CFTR (1.7 ± 
0.2 %/°C), confirming the critical role of the F508 side chain in CFTR coupled domain 
folding1,6 (Fig.1g). Similar to the R1070W mutation27 (9.2 ± 2.3 %/°C), VX-809 (9.8 ± 
0.7 %/°C), C18 (9.6 ± 1.3 %/°C) or C3 (10.8±2.1 %/°C) restored WT-like coupling 
between NBD1 stability (Tm) and ∆F508-CFTR PM expression, supporting the 
possibility that class-I correctors stabilize the NBD1-MSD2 interface (Fig.1g). 
Interestingly, the improvement of WT-CFTR PM expression by NBD1 stabilization 
reinforces the notion that the inherent conformational fluctuation of the NBD1 partly 
accounts for limited processing efficiency of the WT channel27 (Fig.1g).   
 
Mechanisms of action of CFTR correction 
To assess whether VX-809 or C18 can directly bind to ∆F508-CFTR as a PC, the 
functional stability of the temperature-rescued mutant channel was determined in 
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artificial planar phospholipid bilayer27,34. These experiments used the ∆F508-CFTR-
2RK, incorporating R29K and R555K mutations to improve the channel reconstitution 
success by modestly enhancing the PM expression after the 26°C rescue while 
preserving the ∆F508-CFTR channel gating and functional stability defects as reported 
before34 (Supplementary Fig.4a-c). The open probability (Po) of the phosphorylated 
∆F508-CFTR-2RK channel was progressively decreased from 0.21 to 0.09 upon raising 
the temperature from 24°C to 36°C34,35 (Fig.2a-b). In contrast, the Po of the WT was 
increased from 0.35 to 0.47 (Fig.2a-b). VX-809 and C18 prevented the mutant thermal 
inactivation and maintained the Po = 0.21 and 0.26, respectively, at 36°C during the 
course of the measurement (Fig.2a-b and Supplementary Fig.4d), providing evidence 
that these compounds can directly interact with the channel.  
To delineate potential VX-809 target sites, in silico docking was performed on the 
NBD1 crystal structure (PDB:2BBT) and two CFTR homology models3,36 following the 
deletion of the F508 using AutoDock. VX-809 was docked to NBD1-CL1(MSD1), 
NBD1-CL4(MSD2), and NBD1-NBD2 interfaces (Fig.2c, Supplementary Fig.5 and 
Table3). Some of these sites have been reported as putative corrector binding sites37,38. 
To test the in silico predictions, the NBD1-CL4 and NBD1-CL1 interfaces were 
disrupted by R1070W or F508G5,6,27,39 and the CF-causing R170G mutation 
(http://www.genet.sickkids.on.ca/app), respectively, in WT CFTR. The R170G 
substitution probably disrupts the electrostatic interaction between R170 (CL1) and 
E402, E403 and/or E476 (NBD1) (Fig.1a). The F508G interferes with the hydrophobic 
patch formation at the NBD1-CL4 interface while only marginally compromises the 
NBD1 energetics3,27. These events lead to the destabilization of the joint CL1/CL4 
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interface with NBD1 and subsequent misfolding of multiple CFTR domains6. 
Remarkably, the severe processing and PM expression defects of both CL1 and CL4 
interface mutants were largely corrected by VX-809, C18 or C3 (Fig.3a-c). Conversely, 
stabilizing the NBD1-CL4 interface by V510D or R1070W mutation in the absence of 
F508 attenuated the relative efficiency of class-I correctors but not of C4 on ∆F508-3S-
CFTR (Fig.3d and Supplementary Fig.6a). Moreover, V510D mutation which improves 
the WT expression conceivably by stabilizing the NBD1-CL4/CL1 interface and 
marginally the NBD1 itself27, also attenuated the effect of class-I correctors on WT 
CFTR (Supplementary Fig.6b). Surprisingly, V510D but not the R1S mutation, 
substantially corrected the R170G defect (Supplementary Fig.6c), suggesting that the 
NBD1-CL1 interface defect is coupled to that of the NBD1-CL4. The rescue of R170G-
CFTR expression by class-I correctors, however, was partially diminished by the V510D 
mutation (Supplementary Fig.6d). In addition to in silico docking prediction 
(Supplementary Fig.5a, c and e), the stronger effect of VX-809 on the CL1 mutants 
compared to transmembrane (TM) helix 1 mutants, such as G85E and G91R 
(Supplementary Fig.7a), also consistent with the model that VX-809 targets the 
interdomain interface composed of NBD1 and the CL1/CL4, containing the respective 
coupling helices1.  
To further dissect the VX-809 target, we assessed its effect on the steady-state 
expression of WT CFTR domain combinations, representing stalled biosynthetic folding 
intermediates6,40. This approach is favored by the observation that the conformation of 
early folding intermediates is similar between WT and ∆F508-CFTR41. VX-809 
increased the level of WT and ∆F508 MSD1-NBD1 (M1N1) equally, as well as the WT 
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MSD1 and MSD1-NBD1-R, but not the domain combinations that lacked MSD1 
(Supplementary Fig.7a-e), suggesting that VX-809 may target MSD1 and stabilize the 
domain interface composed of CL1/CL4.  
To determine the possible role of VX-809 at the NBD1-NBD2 interface, NBD2 
deletion mutants (CFTR-∆NBD2) were used considering the similar folding 
characteristics of WT and CFTR-∆NBD26-8. Class-I correctors and the R1S mutation 
rescued the ∆F508-CFTR-∆NBD2 PM expression to 50-75 % of its WT counterpart as 
in the case of the full-length molecule (Fig.3e-f), ruling out a significant role of NBD1-
NBD2 or NBD2-MSDs interfaces in the CFTR correction (Supplementary Fig.5c-f). 
This result was in agreement with the prediction of preserved VX-809 binding sites on 
the CFTR-∆NBD2 model (Fig.2c). In contrast, NBD2 deletion virtually eliminated the 
∆F508-CFTR-R1S correction by C4 (a C13 analogue)17 or core-corr-II42 (Fig.3e-f). 
Therefore, we designated C4 and core-corr-II as members of class-II correctors (Fig.1b-c 
and Supplementary Fig.2a). Preventing class-II corrector effect by the NBD2 deletion is 
consistent with in silico docking predictions, supporting that the putative target of C4 
and core-corr-II is the NBD1-NBD2 and/or NBD2-MSD1/2 interface (Supplementary 
Fig.8-9), and with the weaker rescue efficiency of class-II correctors on the NBD1-
MSD1/2 interface mutants (R1070W, F508G or R170G) compared to that of class-I 
correctors (Fig.3a-c). These results are also in line with the observation that the C4 
rescue effect is exerted only after the completion of MSD2 translation40. Although in 
silico docking predicted the regulatory insertion (RI)43 as a possible binding site of class-
II correctors in NBD1 (Supplementary Fig.8-9), this scenario was ruled out because C4 
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remained effective for the ∆F508-CFTR-∆RI containing energetically stabilized 
NBD125,26 (Supplementary Fig.9f).  
 
Chemical chaperones stabilize the human ∆F508-NBD1 
Although none of the correctors tested appears to preferentially stabilize the NBD1 
according to the structural complementation analysis (Fig.1b-c), it remains possible that 
correctors can exert limited conformational stabilization effect on the human ∆F508-
NBD1 similar to that of RDR1 on the mouse ∆F508-NBD122. To assess this possibility, 
first the thermal unfolding propensity of the domain was monitored by differential 
scanning fluorimetry (DSF)27. Initial studies were carried out on the human ∆F508-
NBD1 containing a single solubilizing mutation F494N (∆F508-NBD1-1S), followed by 
validation on the native ∆F508-NBD1 with significantly reduced protein yield and 
increased thermal sensitivity. Most of the available correctors including RDR122, failed 
to counteract the conformational instability of the human ∆F508-NBD1-1S and ∆F508-
NBD1, reflected by their  8~9°C lower melting temperature (Tm) relative to their WT 
counterparts (Fig.4a-c and Supplementary Fig.10a). C6, C11 (dynasore) or C12 weakly 
increased the Tm of ∆F508-NBD1-1S but this effect was minimal on the ∆F508-NBD1 
(Fig.4b-c and Supplementary Fig.10a). Accordingly, C11 neither attenuated the in vitro 
ubiquitination of the unfolded NBD1 by the chaperone-dependent E3 ubiquitin ligase 
CHIP27 (Supplementary Fig.10b) nor enhanced the PM expression of the CD4T-∆F508-
NBD1-1S chimera (see below). In contrast, ATP and chemical chaperones (CCs; 
glycerol, TMAO, myo-inositol and D-sorbitol) substantially enhanced the Tm of ∆F508-
NBD1-1S and ∆F508-NBD1 (Fig.4a-c and Supplementary Fig.10a). The DSF results 
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were substantiated by monitoring the NBD1 in vivo folding in the context of the CD4T-
∆F508-NBD1-1S chimera. PM density measurement of the chimeras, as a validated 
surrogate readout of the biosynthetic processing efficiency6,27, showed that only CCs  
(e.g. glycerol and myo-inositol) and solubilizing mutations (R4S) but none of the 
correctors stabilized the cytosolic ∆F508-NBD1-1S anchored to the truncated CD4 
reporter molecule (Fig.4d). 
Considering the enhanced conformational dynamics of amino acid residues 507-
511 in the isolated ∆F508-NBD1-3S shown by hydrogen deuterium exchange and mass 
spectrometry (HDX-MS)44, we tested whether VX-809 can limit the conformational 
dynamics of this region. We confirmed the accelerated deuteration of the 505-509 amino 
acid peptide in ∆F508-NBD1-1S relative to its WT counterpart44, but not of the 
remaining >60 peptides, representing 98% sequence coverage of NBD1-1S (Fig.4e-h 
and Supplementary Fig.10c). VX-809, however, was unable to suppress the HDX 
kinetics of the 505-509 segment, as well as the other peptides, suggesting that VX-809 is 
unable to elicit localized conformational stabilization on the ∆F508-NBD1-1S (Fig.4e-
h).  
Corrector combinations robustly rescue ∆F508 in BHK cell  
Based on this study and other published data22,38,40, we propose the categorization of the 
∆F508 correctors into three classes (Fig.5a). Class-I (C3, C18 and VX-809) primarily 
stabilizes the NBD1-CL1/4 interface, class-II (core-corr-II and corr-4 analogues [C4, 
C13]) targets NBD2 and/or its interface, and class-III stabilizes the ∆F508-NBD1. Since 
RDR1 stabilize the mouse, but not the human NBD122 (Fig.4), we used CCs, such as 
glycerol as surrogate class-III correctors in our proof-of-principle studies.  
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Combination of chemicals with complementary structural targets is predicted to 
potentiate the individual correctors via ∆F508-CFTR coupled domain-folding and 
phenocopy the combination of suppressor mutations27,28 (Supplementary Fig.1b). While 
class-I corrector (VX-809, C18 or C3) with class-II corrector (C4 or core-corr-II) only 
modestly rescued ∆F508-CFTR PM level (<10% of WT CFTR), combination of class-I 
corrector and glycerol enhanced the ∆F508-CFTR PM expression to 30-50% of the WT, 
supporting that correction of both primary defects is required for the robust ∆F508-
CFTR rescue (Fig.5b). The class-I corrector or glycerol effect that individually achieved 
<8% rescue was further improved by class-II correctors and enhanced the ∆F508-CFTR 
PM expression to ~60-110% of WT (Fig.5b). Similar phenotypes were confirmed by 
monitoring the accumulation of complex-glycosylated ∆F508-CFTR with 
immunoblotting (Fig.5c). Metabolic pulse-chase experiments (Fig.5d-e) and ELISA 
(Fig.5f) revealed that the combined treatment increased the ∆F508-CFTR folding 
efficiency to ~70% of the WT and largely rescued the mutant PM stability defect. Thus, 
both enhanced ER folding efficiency and PM stability of ∆F508-CFTR in the presence 
of two classes of correctors with glycerol account for the WT-like PM expression.  
 
∆F508-CFTR rescue in bronchial epithelia  
The rationally selected chemical combination also significantly potentiated the VX-809 
rescue of the ∆F508-CFTR in polarized respiratory epithelial cells. The ∆F508-CFTR 
PM density in CFBE41o- cells treated with a class-I corrector was enhanced by ~3-fold 
in the presence of 5% glycerol that was further augmented by class-II corrector (C4 or 
core-corr-II), representing ~5 fold increase of the VX-809 effect (Fig.6a). Combined 
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treatment of two classes of correctors with glycerol enhanced the PM density of ∆F508-
CFTR to ~10% of the WT CFTR level, a comparable efficacy to that achieved by low 
temperature (Fig.6a). The VX-809 effect was further potentiated by combination with 
C4, and glycerol and partially restored the ∆F508-CFTR complex-glycosylation 
(Fig.6b), PM stability (Fig.6c), and function at the apical PM in CFBE41o- epithelia 
(Fig.6d-e). Similar enhancement was observed in other polarized epithelial cell models. 
The combined treatment enhanced the PM density of ∆F508-CFTR to ~40% and ~15% 
of the WT level in Madin-Darby Canine Kidney (MDCKII) and human lung papillary 
adenocarcinoma epithelial cells (NCI-H441), respectively (Supplementary Fig.11).  
 
Functional correction of ∆F508-CFTR in CF rectal organoid 
Finally, the efficacy of the mechanism-based corrector combination was evaluated in 
human rectal organoids derived from CF patients homozygous for the ∆F508 mutation45. 
CFTR channel activity was measured by monitoring the forskolin-induced swelling 
(FIS) of organoids, since the cross-sectional area of organoids was proportional with 
CFTR-mediated chloride and coupled water transport45. While class-I corrector (C18 or 
VX-809) modestly improved the FIS of CFTR∆F508/∆F508 organoids, combining it with 
myo-inositol46, a CC selected based on its minimal toxicity, enhanced the ∆F508-CFTR-
dependent FIS to 30-60% of that observed in organoids from healthy individuals (WT) 
(Fig.6f-h). The rescued ∆F508-CFTR mediated FIS was completely prevented with 
CFTR blockers (Inh172 and GlyH101) (Fig.6f-h).  Likewise, organoids expressing non-
functional, truncated CFTR variants (E60X/4015ATTdel) also failed to display any FIS 
(Fig.6h). Remarkably, VX-809, C4 and myo-inositol jointly restored the ∆F508-CFTR-
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dependent FIS by >80% of the WT.  Comparison of individual and dual and triple 
combination effect of correctors on FIS of CFTR∆F508/∆F508 organoids indicates a 2-2.5-
fold potentiation (Fig.6h). Together, these results demonstrate that mechanism-based 
corrector combinations are capable to robustly rescue ∆F508-CFTR folding and function 
in cell culture models and primary human CF organoids. 
Interestingly, class-I, class-II corrector or glycerol also augmented the PM 
expression of WT CFTR that has an intrinsic low folding efficiency (~30%)1 
(Supplementary Fig.12a). The WT CFTR rescue efficiency by VX-809 or C18 but not 
C4 was suppressed in the presence of V510D mutation and, to a lesser extent by 3S or 
R4S mutation (Supplementary Fig.12b), consistent with the limited conformational 
instability of the NBD1-MSDs interface and NBD1 in WT CFTR27. These observations 
with the overlapping VX-809 in silico docking data on ∆F508 and WT CFTR 
(Supplementary Fig.12c), as well as MSD1 stabilization are consistent with the 
possibility that VX-809, similarly to the V510D mutation, targets the conformationally 
unstable WT NBD1-MSD1/2 interface. 
 
Discussion 
Here we show that combination of correctors targeting complementary conformational 
defects can overcome their individually modest impact and synergistically restore the 
∆F508-CFTR processing and PM channel function. Using in vivo, in vitro, and in silico 
analyses, we identified subsets of correctors that preferentially target the primary 
conformational defect at the NBD1-MSD1(CL1)/MSD2(CL4) interface (class-I) or the 
consequential NBD2 misassembly (class-II). None of the tested correctors belong to 
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class-III that targets the human ∆F508-NBD1 energetic defect. Only CCs, such as 
glycerol and myo-inositol, can substitute for a class-III corrector by stabilizing the 
human ∆F508-NBD1 both in vitro and in vivo. While we cannot rule out that glycerol 
has multiple targets in ∆F508-CFTR, NBD2 deletion diminished the glycerol effect on 
PM expression and complex-glycosylation of ∆F508-R1S-CFTR, but left the ∆F508-
CFTR-R1070W expression largely unaffected (Fig.3e-f and Supplementary Fig.7f-g). In 
addition, glycerol rescued the PM level of ∆F508-CFTR-R1070W similar to that of the 
NBD1 stabilizing mutations24 (Supplementary Fig.7f-g). These observations suggest that 
glycerol may primarily stabilize the NBD1. The proposed corrector classification also 
provides a plausible explanation for the additive effect of C3 (class-I) and C4 (class-
II)47,48 or VX-809 (class-I) and C4 (class-II), the attenuated efficiency of C3 and VX-
80914 and the potentiation of class-I by CCs (as surrogate of class-III) (Fig.5-6). The 
limited synergy between class-I and class-II correctors in the absence of CC may imply 
that suppression of ∆F508-CFTR primary defects is a prerequisite for correction of the 
secondary NBD2 defect. 
 By selectively increasing the ER folding efficiency and the PM stability in 
multiple cellular models, VX-809 was predicted to overcome a kinetic folding trap 
and/or stabilize the native-like conformer by direct interaction with ∆F508-CFTR14.  The 
inhibition of the ∆F508-CFTR-2RK thermal inactivation by VX-809 or C18 suggests 
that these correctors can directly interact with the mutant at the single molecule level. 
Although VX-809 prevented the functional inactivation upon raising the temperature 
from 24°C to 36°C, extended exposure to 36°C attenuated the VX-809- rescue effect 
probably due to the stabilization of only the NBD1-MSD1/2 interface defect. This 
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interpretation is consistent with the modest effect of NBD1-MSD1/2 interface genetic 
stabilization49, compared to that of the NBD135, and may explain the negligible effect of 
VX-809 on the ∆F508-CFTR-I539T thermal inactivation reported recently38. Notably, 
direct interaction of C3 as well as potentiators P1 and VX-770 with purified CFTR was 
also inferred based on their modulation of the channel ATPase and transport 
activity24,50,51. 
 Definitive identification of VX-809 binding site(s) in the absence of a 
functionally inert, cross-linkable adduct remains a challenge and is further exacerbated 
by the coupled folding and misfolding mechanism of CFTR domains6,8 that may allow 
allosteric corrections of folding defects from different binding sites. However, our 
analysis by in silico predictions, in concert with in vitro assays (DSF and HDX-MS) 
using isolated human NBD1s and in vivo studies using full-length CFTRs with deletion 
and point mutations, suggest that the NBD1-CL1/4 represents a primary target of VX-
809, a conclusion that partly overlaps with a recent proposition38.  
Importantly, mutations confined to the TM helix-1 (G91R) and CL2 (M266R, 
W277R) of MSD1 could also be partially rescued, presumably via targeting the coupled 
interface defect at the NBD1-CL1/4. These results, jointly with those obtained using 
CFTR fragments and CL1 mutations, provide a plausible model of VX-809 action that 
binds to MSD1 and stabilizes the CL1-CL4 coupling helix, a critical step to form the 
proper interactions of NBD1 first with MSD1 then with MSD2 and ultimately facilitate 
cooperative domain assembly upon completion of NBD2 translation27,28,38. 
Counteracting the processing defect of the CF causing R170G and other missense 
mutation localized to the TM helix-1 and CL1/4 described here and previously38 by 
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class-I correctors also suggests that VX-809 may be successfully utilized alone or in 
combination in a variety of rare CF mutations.  
While the additive effect of corrector pairing has been previously observed14,47,48, 
the rationale for corrector combination remained elusive. Our most important finding is 
that mechanism-based classification of correctors permitted a rationally designed 
corrector combination approach that achieved a significant improvement in ∆F508-
CFTR rescue efficiency. Chemical correction of NBD1, NBD1-MSD1/2 interface, and 
NBD2 instabilities almost completely restored the ∆F508-CFTR folding, PM expression, 
stability, and function in BHK cells. The ∆F508-CFTR rescue was weaker in kidney and 
respiratory epithelial cells (10-30% of the WT) than in BHK cells. This could be 
attributed to modest NBD1 stabilization by reduced glycerol concentration (5%) that 
was required to maintain epithelial polarity.  
While the robust combination correction of ∆F508-CFTR transport function in 
human CFTR∆F508/∆F508 organoids may be an overestimate due to the rate limiting ion 
transport capacity of the basolateral PM in WT intestinal organoid, the VX-809-induced 
∆F508-CFTR chloride transport was augmented almost 4-fold by class-II compound and 
CC based on the FIS measurements. Considering that VX-809 improves ∆F508-CFTR 
PM function to ∼15% of WT in primary human bronchial epithelia14 with marginally 
translatable clinical benefit21, it is reasonable to assume that structural defect-targeted 
corrector combination will eventually confer sufficient CFTR transport capacity in 
respiratory epithelial cells to achieve significant clinical improvements in most 
CFTR∆F508/∆F508 patients. 
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 None of the available correctors but CCs can counteract the human ∆F508-
NBD1 conformational defect according to in vitro and in vivo folding studies. This 
represents a bottleneck of CF pharmacological therapy, since systemic administration of 
CCs is not feasible. To achieve improved pharmacological corrections in combination 
with class-I correctors (e.g. VX-809), identification of NBD1 stabilizer is required. 
Initial isolation of PCs stabilizing the NBD1 could be envisioned by high-throughput 
screening (HTS) of diverse compounds or fragment libraries in vitro, in vivo or in silico 
using ∆F508-NBD1 or ∆F508-CFTR cell-based functional or biochemical assays17,22. 
Exploiting NBD1-MSD1/2 interface stabilization by second site suppressor mutation or 
class-I correctors (e.g.VX-809) may bias HTS efforts towards the isolation of NBD1 
stabilizing small molecules. We believe that the successful identification of NBD1 
stabilizer would make the mechanism-based corrector combination therapy feasible for 
most CF patients. 
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Figure legends 
Figure 1. Combination of corrector and suppressor mutations restores ∆F508-
CFTR folding, PM expression and function. 
(a) NBDs-MSDs interfaces in the CFTR open structural model36. Some critical interface 
residues are indicated. (b) Relative PM density of ∆F508-CFTR containing R1S (Y-axis) 
or R1070W (X-axis) upon corrector treatment was measured by ELISA in BHK cells 
(n=6-12). Correctors indicated by black symbols are listed in Supplementary Fig.2a. (c) 
Structural preference of correctors to NBD1-MSD2 interface over NBD1 stability defect 
was visualized by plotting sum of correction (ResR1S + ResR1070W, Y-axis) as a function 
of log2  ratio of the augmented PM density of ∆F508-CFTR with R1S and R1070W 
(ResR1S/ResR1070W, X-axis). (d) Maturation efficiency of ∆F508-CFTR was measured by 
metabolic pulse-chase experiments. B, immature core-glycosylated; C, mature complex-
glycosylated form. (e-f) PM density (e; n=8-20), and function (h; n=3-4) of ∆F508-
CFTR with or without suppressor mutation was measured by ELISA and apical Cl- 
current (ICl(apical)), respectively, in CFBE41o- cells. Na+/K+-ATPase (ATPase) was 
used as a loading control. (g) Correlation between Tm of NBD1 variants of 0S, 1S, 3S, 
R1S and R4S (listed in Table S2) and PM density of the respective CFTR variants in 
BHK cells (n=8-12) in the presence or absence of correctors. The data were fitted by 
linear regression analysis and slopes were listed in the result as %/°C unit. Correctors 
(C3 at 10 µM; C18 or VX-809 at 3 µM) were applied for 24 h at 37°C. Data are means ± 
SEM.  
 
Figure 2. VX-809 functions as a pharmacological chaperone of CFTR. 
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(a-b) Effect of VX-809 and C18 correctors on thermal inactivation of the ∆F508-CFTR-
2RK reconstituted into artificial phospholipid bilayer. (a) Representative channel activity 
is shown for WT or ∆F508-2RK CFTR at 24°C, 30°C or 36°C during the temperature 
ramp in the absence or presence of 3 µM VX-809. The processing defect of the ∆F508-
CFTR variants was rescued at 26°C prior to microsome isolation. Channel activity is 
also shown at higher time resolution for each condition at 36°C. The closed (c) state of 
the channels is indicated. The control gating of ∆F508-CFTR-2RK was derived from 
separate experiments at 24°C and 27°C plus 36°C. Incorporation of two channels was 
observed at 27-36°C.  The ∆F508-CFTR-2RK activity was recorded in separate 
experiment at 24°C plus 30°C and 36°C in presence of VX-809. (b) The Po of PKA-
activated CFTRs was analyzed at the indicated temperature as described in panel a. 
Cumulative duration of single channel experiments for WT and ∆F508-CFTR-2RK was 
at least 15 min. Number of independent experiments is indicated in the bars (n=8-25). 
Data represent means ± SEM and significance was tested by paired t-test. *<0.05, 
**p<0.01. (c) VX-809 in silico docking to open ∆F508-CFTR (top panel) or ∆F508-
CFTR-∆NBD2 model (bottom panel) obtained by AutoDock. The first four VX-809 
clusters are ranked based on their lowest binding energy pose in ascending order and are 
illustrated on the model using PyMOL. For clarity, NBD2 and R-domain are hidden 
from the full-length model. Red, blue, magenta, cyan: clusters of VX-809 with 
increasing binding free energy. 
 
Figure 3.  Evaluating corrector mechanism by using CFTR variants. 
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 (a-c) Effect of correctors (10 µM C3 or C4, 3 µM C18 or VX-809 for 24 h at 37°C) on 
cellular expression (upper) and PM density (lower) of R1070W (a), F508G (b), and 
R170G (c) CFTR variants in BHK cells, measured by Western blotting and cell surface 
ELISA (n=8), respectively. (d) Effect of V510D or R1070W mutation on the PM density 
of corrector treated ∆F508-CFTR-3S measured by cell surface ELISA in BHK cells and 
expressed as % of the respective DMSO control (n=8). Same results are also shown in 
Supplementary Fig.6a as % of WT. (e-f) Effect of NBD2 deletion (∆NBD2) on corrector 
effect measured by the PM density (e, n=6-9) and cellular expression (f) of ∆F508-
CFTR-R1S. Correctors (5 µg/ml core-corr-II, 10% glycerol, others are same as in panel 
a-c) were added for 24 h at 37°C. Data represent means ± SEM.  
 
Figure 4. Effect of correctors on the isolated NBD1 stability in vitro and in vivo. 
(a-c) Melting temperature (Tm) of human ∆F508-NBD1-1S (a) or ∆F508-NBD1 (b, c) 
was determined by differential scanning fluorimetry (DSF)6,27 as described in Methods. 
The indicated correctors or chemical chaperones (CC) (see Supplementary Table 1) were 
present during thermal unfolding at the following concentration: 3 µM and 10 µM C1, 
C2, C3, C4, C5, C6, C7, C9, C11, C12, C13, C14, C17 and CoPo; 10 µM and 20 µM 
C8, C15 and C16; 1 µM and 3 µM C18 and VX-809, 5 µM and 15 µM RDR1; 2.5 µg/ml 
and 5 µg/ml core-corr-II; 5% and 10% glycerol; 150 mM and 300 mM TMAO, taurine, 
myo-inositol and D-sorbitol. WT-NBD1-1S or WT-NBD1 was used as a positive 
control. (c) Tm of ∆F508-NBD1 was determined by DSF as in panel b. Data represent 
mean ± SEM (n=3). Change in Tm was considered statistically significant if they were > 
± 3SD (30.2 ± 0.4°C) of DMSO treated ∆F508-NBD1 Tm. (d) PM density of CD4T-
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∆F508-NBD1-1S in COS7 cells was measured by PM ELISA using anti-CD4 Ab. The 
ELISA signal of mock-transfected cells is also indicated. Cells were treated with 
corrector for 24 h at 37°C. CD4T-WT-NBD1-1S (WT-1S) and CD4T-∆F508-NBD1-
R4S (∆F-R4S) were used as positive control. Data represents mean ± SEM (n=8-12). (e-
h). Conformational dynamics of wt and ∆F508-NBD1-1S was determined by HDX-MS 
following 5 min D2O labelling in the presence or absence of 10 µM VX-809. Data are 
means ± SEM (n=3). Representative peptides are shown from > sixty peptides obtained 
by pepsin digestion.   
 
Figure 5. Combination of correctors targeting distinct structural defects completely 
restores ∆F508-CFTR folding, PM expression and stability in BHK cells.  
(a) Schematic model shows the proposed targets of available correctors based on in 
vitro, in vivo and in silico analysis. Chemical chaperones (CC, e.g. glycerol and myo-
inositol) preferentially, but presumably not exclusively stabilize the ∆F508-NBD1. VX-
809, C18 and C3 target the NBD1-MSD1/2 interface and C4 and core-corr-II target the 
NBD2. (b-f) ∆F508-CFTR PM density (b; n=6-12), cellular expression (c), ER folding 
efficiency (d-e; n=3-4) and PM stability after 4 h (f; n=5-12) were determined upon 
treatment with correctors (10 µM C3 or C4; 3 µM C18 or VX-809, 5 µg/ml core-corr-II; 
10% glycerol) or their combinations in BHK cells by cell surface ELISA, Western 
blotting, metabolic pulse-chase technique and cell surface ELISA, respectively. All data 
represent means ± SEM.  
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Figure 6. Corrector combination restores ∆F508-CFTR functional expression in 
polarized epithelial cell lines and rectal organoids from ∆F508 CF patients.  
(a-e) ∆F508-CFTR PM density (a, n=7-22), cellular expression (b), PM stability (c, 
n=16) and function (d, n=3-4) in CFBE41o- cells. Correctors (10 µM C3 or C4, 3 µM 
C18 or VX-809, 2.5 µg/ml core-corr-II, 5% glycerol [Gly]) were applied for 24 h at 
37°C. For comparison, ∆F508-CFTR was rescued by low temperature at 26°C or 30°C 
for 36-48 h. (d) Representative records of forskolin and 100 µM genistein (gen) 
activated ∆F508-CFTR ICl(apical) following corrector treatment are shown. (e) 
Summary of the peak, Inh172-sensitive ICl(apical) of ∆F508-CFTR in CFBE41o- cells 
after corrector treatment (n=3-4). (f) Fluorescence laser confocal images of calcein-
green loaded CF rectal organoids before and after forskolin-induced swelling (FIS) for 
60 min in the presence of correctors (2 µM, VX-809, C4 and/or 125 mM myo-inositol 
(myo)), and inhibitor (Inh; 50 µM CFTR inhibitor-172 and GlyH-101). (g) Time course 
of FIS of CF organoids from a representative experiment. Organoids were treated as 
described in Methods. FIS was expressed as percentage of initial cell cross-sectional 
area before forskolin stimulation. (h) FIS was expressed as percentage of the area of 2 
µM VX-809 treated cells after 60 min of FIS. Besides the measured FIS (red bar), the 
predicted sum of the individual corrector effect (2 µM C3, C4, C18; 0.1 or 2 µM VX-
809; 125 mM myo-inositol) is indicated, assuming additive effect (blue bar). The mean 
FIS from three healthy controls (WT) is included. No FIS was observed after treatment 
of myo-inositol, C4 and VX-809 in organoids carrying E60X/4015ATTdel CFTR 
mutant. Data represent means ± SEM from six independent experiments performed on 
three ∆F508 homozygous patients. 
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Online Methods   
Cell lines 
Full-length and truncated human CFTR variants with the 3HA-tag in the 4th extracellular 
loop52 were constructed by PCR mutagenesis (Supplementary Table 2). Detailed 
information on PCR mutagenesis is available from the authors on request. BHK cells 
stably expressing CFTR variants were generated and grown as previously27. MDCK type 
II cells stably expressing CFTR-3HA variants were generated by lentivirus infection 
under puromycin selection (1-5 µg/ml) and grown in Dulbecco's modified Eagle's 
medium (DMEM) (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine 
serum (FBS). CFBE41o- Tet-on and NCI-H441 Tet-on cells stably expressing CFTR-
3HA variants under tetracycline responsive promoter were generated by lentivirus 
transduction using the Lenti-X TetON Advanced Inducible Expression System 
(Clontech, Mountain View, CA) under puromycin (3 µg/ml) and G418 selection (0.2 
mg/ml) and grown in minimal essential medium (MEM, Invitrogen) supplemented with 
10% FBS, 2 mM L-glutamine and 10 mM HEPES, and RPMI-1640 Medium (ATCC) 
supplemented with 10% FBS. For propagation, the CFBE41o- cells were cultured in 
plastic flasks coated with an extracellular matrix (ECM mix) consisting of 10 µg/ml 
human fibronectin (EMD), 30 µg/ml PureCol collagen preparation (Advanced 
Biomatrix) and 100 µg/ml bovine serum albumin (Sigma-Aldrich) diluted in LHC basal 
medium (Invitrogen). The CFTR-3HA expression was induced by 0.5 or 1 µg/ml 
doxycycline treatment for 4 days.  
 
Antibodies and Reagents 
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Antibodies (Abs) were obtained from the following sources. Monoclonal anti-CFTR Ab 
L12B4 (recognizing NBD1) and M3A7 (recognizing NBD2) were purchased from 
Millipore Bioscience Research Reagents (Temecula, CA). Mouse monoclonal anti-HA 
Ab was from Covance Innovative Antibodies (Berkeley, CA). Chemicals were obtained 
from Sigma-Aldrich (St. Louis, MO) at the highest grade available. Most of the CFTR 
correctors were obtained from Cystic Fibrosis Foundation Therapeutics (CFFT), VX-809 
from Selleck (Houston, TX), class II compounds were synthesized as described42. All of 
the correctors used in this study are listed in Table S1. 
 
NBD1 protein purification 
Recombinant human NBD1 proteins were purified from E. coli as previously 
described27. The NBD1 protein was concentrated to 3–5 mg/ml in buffer containing 150 
mM NaCl, 1 mM ATP, 2 mM MgCl2, 1 mM TCEP, 10% Glycerol and 10 mM HEPES, 
pH 7.8. 
 
Microsome Preparation 
Microsomes were isolated by differential centrifugation from BHK cells stably 
expressing 3HA-tagged WT or ∆F508-2RK CFTR as described27. To enrich for the 
complex-glycosylated ∆F508-2RK CFTR, cells were incubated at 26°C for ∼36 hours 
followed by treatment with 150 µg/ml cycloheximide (CHX, 26°C for 12 h) before 
microsome isolation52. WT CFTR expressing cells were treated with 150 µg/ml CHX for 
3 hours to eliminate the ER-localized core-glycosylated form. 
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Planar lipid bilayer studies  
WT or ∆F508 CFTR reconstitution and channel activity were essentially measured as 
described previously27. A planar phospholipid bilayer was made of a 2:1 (w/w) mixture 
of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (POPE) and 1-palmitoyl-2-
oleoyl-sn-glycero-3-phospho-L-serine (POPS, Avanti Polar Lipids, Alabaster, AL) in n-
decane solution at a final lipid concentration of 25 mg/ml and formed over a 200 or 250 
µm diameter hole in a polystyrene chamber by monitoring the increase in its capacitance 
to 150–200 pF. The bilayer was bathed in symmetrical 300 mM Tris-HCl, 10 mM 
HEPES (pH 7.2), 5 mM MgC12, and 1 mM EGTA. Microsomes (10-20 µg proteins) 
isolated from CFTR expressing BHK cells were prephosphorylated in the presence of 
100U/ml protein kinase A (PKA) catalytic subunit (Promega) and 2 mM MgATP at 
room temperature for 10 min, added to the cis compartment and fused to planar lipid 
bilayer. CFTR channel activity was recorded in the presence of 100 U/ml PKA catalytic 
subunit and 2 mM MgATP. Currents were measured with a BC-535 amplifier (Warner 
Instrument, Hamden, CT). Voltage was clamped at Vm = −60 mV. In temperature ramp 
experiments the chamber was heated from room temperature to 36°C at a rate of ∼1-
2°C/min. Single channel activities were acquired using pClamp 8.1 (Axon Instruments) 
with 10 kHz, filtered at 200 Hz with low pass 8 pole Bessel filter and stored digitally. 
Records were filtered at 50 Hz and analyzed using Clampfit 10.3 (Axon Instruments). 
We applied 50% cut off between open and closed levels and events shorter than 10 ms 
were excluded from the analysis. Single channel open probability (Po) was determined as 
NPo divided by the number of channels, where NPo was obtained from event detection 
features of Clampfit 10.3 and N represents the number of channels. 
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HDX-MS 
Localized conformational dynamics of isolated NBD1s was measured by HDX-MS 
essentially as described44. HDX was initiated by mixing 1-2 µL of NBD1 stock solution 
to 15 volumes of D2O-based buffer (pD 7.5, based on pD = pHread + 0.40)53 containing 
150 mM NaCl, 1 mM ATP, 2 mM MgCl2, 1 mM TCEP and glycerol, resulting in a final 
D2O concentration of more than 90 % (v/v). The final concentration of glycerol was 
adjusted to 1%. The mixtures were incubated for 15 sec, 1min, 5 min, 15 min, 1 h and 2 
h at room temperature and then quenched by adding a 2-2.5 µL aliquot of the mixture to 
300 mM phosphate buffer containing 8 M urea, pH 2.5 (quenching buffer). Quenched 
solutions were flash frozen in MeOH containing dry ice and samples were stored at -
80°C. 
Prior to high performance liquid chromatography (HPLC)-MS analysis, the 
labeled protein solutions were thawed, and immediately loaded onto the injection valve. 
Deuterated NBD1 was digested in an on-line immobilized pepsin column prepared in-
house. On-line pepsin digestion was carried out at flow rate of 50 µL/min for ∼1.5 min, 
and resulting peptides were trapped on C18 trapping column (Optimized Technologies, 
Oregon city, OR). Following desalting for 1.5 min (at 150 µl/min flow rate), peptides 
were loaded onto a C18 column (1 mm i.d. × 50 mm, Thermo Fisher Scientific, 
Waltham, MA) through a six-port valve. Peptides were separated using a 13-90% linear 
gradient of acetonitrile containing 0.1% formic acid for 6 min at 50 µl/min. 
Chromatographic separation was performed using an Agilent 1100 HPLC system. To 
minimized back-exchange, the column, solvent delivery lines, injector and other 
accessories were immersed in an ice bath. The C18 column was directly connected to the 
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electrospray ionization source of LTQ Orbitrap XL (Thermo Fisher Scientific). Mass 
spectra of peptides were acquired in positive-ion mode for m/z 200-2000. Identification 
of peptides was carried out in separate experiments by tandem MS (MS/MS) analysis in 
data-dependent acquisition mode and using collision-induced dissociation. All MS/MS 
spectra were analyzed using SEQUEST program (Thermo Fisher Scientific). Searching 
results from SEQUEST were further manually inspected and only those verifiable were 
considered in HDX analysis. Triplicate measurements were carried out for each time 
point. HDExaminer (Sierra Analytics, Modesto, CA) were used to determine the 
deuteration level as a function of labeling time. The deuterium level of peptides were not 
corrected for back-exchange, and therefore presented values reflect the relative exchange 
levels across the protein samples54.  
 
Differential scanning fluorimetry (DSF)  
Melting temperature of recombinant human NBD1 was measured as previously27. DSF 
scans of NBD1 (7-12 µM) were obtained in 150 mM NaCl, 20 mM MgCl2, and 10 mM 
HEPES, pH 7.5 and were performed using a Stratagene Mx3005p (Agilent 
Technologies, La Jolla, CA) qPCR instrument in the presence of 2X Sypro Orange.  The 
medium ATP concentration was kept at 2.5 mM unless otherwise indicated.  
 
Measurement of CFTR cell surface density and stability 
Cell surface CFTR-3HA density and stability was measured by ELISA using anti-HA 
Ab as previously52. The PM density of CD4-NBD1 chimeras was measured by cell 
surface ELISA using anti-CD4 (OKT4) Ab in transiently transfected COS-7 cells as 
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described6,27. Cell surface density of CFTR and CD4-NBD1 chimeras was normalized 
with protein concentration based on BCA assay. Data were presented as mean values ± 
SEM from at least 2 independent experiments that consist of multiple (3-8) 
measurements.  
 
Western blotting and pulse-chase experiments 
Western blotting and pulse-chase experiments were performed as previously52. Cells 
were treated with correctors for 24 h at 37°C and during the pulse-labeling and chase 
period.  
 
Apical Cl- current
  
(ICl(apical)) measurement 
Apical Cl- current measurements was essentially performed as described13. CFBE41o- 
cells were plated on ECM-mix coated 12 mm Snapwell filters (Corning, Corning, NY) at 
a density of 1 x 105 cells/cm2. Polarized epithelia (≥ 5 days post confluence) were 
mounted in Ussing chambers, bathed in Krebs-bicarbonate Ringer and continuously 
bubbled with 95% O2 and 5% CO2. To impose a chloride gradient, Cl- was replaced by 
gluconate in the apical compartment. To functionally isolate the apical PM, the 
basolateral PM was permeabilized with 100 µM amphotericin B and the epithelial 
sodium channel was inhibited with 100 µM amiloride. CFTR activity was stimulated by 
apical forskolin (0.03-10 µM) and genistein (100 µM) followed by the addition of CFTR 
inhibitor 172 (Inh172, 20 µM) to determine CFTR-specific apical Cl- current 
(ICl(apical)). Measurements were performed at 37°C. The transepithelial resistance 
(TER) of CFBE was predominantly between 200-1700 Ω/cm2. Although combination of 
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three chemicals, including glycerol, reduced the TER of permeabilized CFBE cells to 
<200 Ω/cm2, the CFTR-mediated ICl(apical) was measured by monitoring only the 
CFTR-Inh172-sensitive component of the forskolin and genistein stimulated ICl(apical). 
 
In silico docking 
In silico docking of VX-809, C4 and core-corr-II was performed using AutoDock 4.2. 
Preparation of the proteins. Proteins were prepared initially in PDB format. The structure 
of the ∆F508-NBD1 was obtained from the PDB database (PDBID:2BBT)44. The F504N 
and Q646R solubilizing mutations were reverted back to F504 and Q646 followed by 
energy minimization in SYBYL (Tripos Inc.) using the AMBER force-field55 with 
AMBERF99 charges56. Two full-length models, one representing the closed state 
(http://dokhlab.unc.edu/research/CFTR/home.html)3, the other representing the open 
state36 were selected for docking. For comparability, both models were trimmed to 
contain amino acids 81-365, 391-648, 855-1154, and 1208-1429. The F508 was deleted 
followed by the adjustment of the neighboring residues using the Modloop server57 and 
by energy minimization using the AMBER force-field with AMBERF99 charges56. All 
the amino acid numbers mentioned in the paper correspond to the amino acid numbering 
in the WT CFTR. 
Preparation of ligands. Ligands were prepared in mol2 format. VX-809 was downloaded 
from the PubChem Compound Database in 3D sdf format and converted to mol2 format 
by SYBYL. Molecules C4 and core-corr-II were drawn in 2D using ChemBioDraw Ultra 
12.0 (CambridgeSoft) and saved in mol2 format. Their coordinates were copied to the 
PRODRG server58 to obtain an initial 3D structure. The resulting mol2 files of C4 and 
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core-corr-II were corrected to contain appropriate atom types and were subjected to 
energy minimization in SYBYL. Tripos force-field with Gasteiger-Hückel charges were 
used until the RMS gradient of the energy derivative reached 0.01 kcal/mol/Å. 
Running the docking simulations. The docking was performed using AutoDock59. Input 
files were prepared using AutoDock 4.2 with AutoDockTools (MGLTools 1.5.4). 
Ligands were loaded with Gasteiger charges and were saved in pdbqt format. Polar 
hydrogen atoms and Kollmann charges were added to the proteins. The grid box was 
centered on coordinates 95 Å, 70 Å, 170 Å and its size was set to 70Å x 70Å x 70Å with 
0.5 Å spacing to include the two NBDs and the coupling helices (Fig.S5b). To achieve 
this box size, AutoDock was compiled with a value of MAX_GRID_POINTS higher 
than the default 126 that allowed us to set 140 grid points in each direction. Lamarckian 
Genetic Algorithm was used for docking with default settings, except for the parameters 
ga_pop_size (300) and ga_num_evals (30,000,000) to perform exhaustive sampling. 
Three docking simulations with different random seeds for each drug and structure were 
run on the Hungarian HPC infrastructure (NIIF Institute, Hungary). 250 hits from each 
run were collected. 
Analysis of the docking simulations. All the 750 poses for each docking were used for 
analysis. These conformations were analyzed using SciPy (http://www.scipy.org) and in 
house written python scripts. A python package for SciPy called hcluster was used to 
perform hierarchic clustering based on root means square deviation (RMSD) using the 
centroid distance measure. The threshold for forming flat clusters was set to include 
conformations with RMSD values smaller than 3 Å into each cluster. Binding poses 
were clustered by RMSD and ordered by the binding pose with the lowest binding free 
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energy in each cluster. The four clusters, in which the pose with the lowest binding free 
energy exhibits one of the lowest binding free energies, are shown in figures, which 
were prepared in PyMOL (DeLano Scientific LLC). The CFTR amino acid binding sites 
of correctors were determined using PyMOL by selecting residues in less than 4 Å 
distance from every molecule in each cluster. 
 
In vitro ubiquitination of NBD1 
In vitro ubiquitination of purified ∆F508-1S-NBD1 was performed as previously27. 
NBD1-1S (1 µM) was incubated for 5 min at 34°C with 0.1% DMSO (as control) or C11 
in reaction buffer (20 mM HEPES, pH 7.5, 50 mM NaCl, 5 mM MgCl2, 2 mM DTT, 20 
µM MG-132, 5 µg/ml leupeptine, 5 µg/ml pepstatin A) in the presence of 2 µM Hsc70. 
After the heat denaturation, the CHIP-mediated NBD1 ubiquitination was initiated by 
incubation at 26°C for 2 hours with 0.1 µM E1, 4 µM UbcH5c, 3 µM CHIP and 10 µM 
ubiquitin (Sigma). NBD1was analyzed by immunoblotting with anti-NBD1 (L12B4) 
antibody. 
 
Crypt isolation and organoid culture from human rectal biopsies 
Crypt isolation and culture of human intestinal organoids have been described 
previously60. Rectal suction biopsies were obtained for intestinal current measurements 
(ICM) during standard CF care by a procedure described previously45 that has been 
approved by the Ethics Committee of the University Medical Centre Utrecht and the 
Erasmus Medical Centre of Rotterdam. In short, rectal biopsies were washed with cold 
complete chelation solution and incubated with 10 mM EDTA for 60-120 minutes at 
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4°C. Supernatant was harvested and EDTA was washed away. Crypts were isolated by 
centrifugation and embedded in matrigel (growth factor reduced, phenol-free, BD 
bioscience) and seeded (50-100 crypts per 50 µl matrigel per well) in 24-well plates. The 
matrigel was polymerized for 10 minutes at 37°C and immersed in complete culture 
medium: advanced DMEM/F12 supplemented with penicillin/streptomycin, 10 mM 
HEPES, Glutamax, N2, B27 (all from Invitrogen), 1 mM N-acetylcysteine (Sigma) and 
growth factors: 50 ng/ml mEGF, 50% Wnt3a-conditioned medium and 10% Noggin-
conditioned medium, 20% Rspo1-conditioned medium, 10 µM Nicotinamide (Sigma), 
10 nM Gastrin (Sigma), 500 nM A83-01 (Tocris) and 10 µM SB202190 (Sigma). The 
medium was refreshed every 2-3 days and organoids were passaged 1:4 every 7-10 days. 
Organoids from passage 1-10 were used for confocal live cell imaging. 
 
CFTR transport activity of human rectal organoids 
Organoids were seeded from a 7 day-old culture in 4 µl matrigel placed into a flat-
bottom 96-well culture plate (Nunc) and commonly contained 40-80 organoids and 100 
µl culture medium. To visualize volume changes, one day after seeding, organoids were 
loaded with 10 µM calcein-green for 60 min (Invitrogen). After calcein-green treatment 
(with or without CFTR inhibition), 5 µM forskolin was added and the organoids 
morphology was monitored by time-lapse fluorescence laser confocal microscopy 
(LSM710, Zeiss, 5x objective). To inhibit CFTR, organoids were pre-incubated with 50 
µM CFTR
 
Inh-172 and 50 µM GlyH-101 (Cystic Fibrosis Foundation Therapeutics, Inc) 
for 3 h. Images were collected every 10 min for 90 min in a top stage incubator (5% CO2  
at 37°C). Each condition was monitored in triplicate wells. For ∆F508-CFTR correction, 
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organoids were pre-incubated for 20-24 hours with 2 µM C4, 2 µM C18, 100 nM or 2 
µM VX-809 or 125 mM myo-inositol (Sigma-Aldrich) as single treatment or in 
combinations. DMSO concentration was identical under all conditions and did not 
exceed 0.2 % (w/v). The organoid surface area was quantified using Volocity 
(Improvision) imaging software. The normalized total organoid surface area was 
calculated and averaged from three individual wells per condition. The area under the 
curve (AUC) was calculated using Prism (GraphPad Software).  
 
Statistical analysis. Results are presented as mean ± SEM for the indicated number of 
experiments. Statistical analysis was performed by two-tailed Student's t-test with the 
means of at least three independent experiments and the 95% confidence level was 
considered significant. 
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 Supplementary Figure 1. Schematic models of CFTR folding and ∆F508-induced 
misfolding.  
(a) In the WT CFTR, MSD1 (M1), NBD1 (N1), MSD2 (M2) and NBD2 (N2) folds co-
translationally to metastable states. Coupled domain folding and assembly facilitate 
proper domain-domain interaction and vice versa, and energetically favor the native 
tertiary structure formation of CFTR. Progressive enthalpic stabilization of individual 
domains during co- and post-translational folding is indicated by pseudo-colors. In case of 
the ∆F508 mutation, both NBD1 energetics and domain-domain interactions (primarily 
the NBD1-MSD1/2 interface) are impaired due to the conformational and topological 
defects, rendering all four major domains structurally unstable6. (b) Strategies to rescue 
the ∆F508-CFTR folding defect. While either stabilization of ∆F508-NBD1 or the NBD1-
MSD2 interface by second site suppressor mutations such as 3S and R1S or R1070W and 
V510D, respectively, achieves modest improvement in the ∆F508-CFTR folding (<20%), 
simultaneous stabilization of these primary structural defects can lead to robust rescue  
(~80%)26. In analogy, available correctors may only restore one of the primary structural 
defects that may account for the limited rescue efficiency of ∆F508-CFTR. Corrector 
pairs acting on different primary structural defects, however, likely restore ∆F508-CFTR 
folding synergistically. Suppressor mutations can be instrumental for a structural based 
corrector screening to identify correctors that either stabilize the NBD1 and/or the NBD1-
MSD2 interface based on the possible synergism.  
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Supplementary Figure 2.  Differential correction efficiency of ∆F508 CFTR 
containing stabilized NBD1 or NBD1-MSD2 interface in BHK cells. 
(a) PM density of ∆F508-CFTR containing R1S (left) or R1070W (right) mutations was 
measured by cell surface ELISA using anti-HA Ab and expressed as % of WT CFTR. 
BHK cells, stably expressing the indicated construct, were treated with correctors for 24 h 
at 37°C. These results were also plotted in Fig.1b-c. Red and green bars indicate 
correctors that belong to class-I and class-II, respectively. Grey bars represent dual acting 
corrector-potentiator compounds. Data are means ± SEM (n=6-12). The augmented PM 
density of ∆F508-CFTR after corrector treatment in the presence of either R1S (ResR1S) or 
R1070W (ResR1070W) mutation is expressed as percentage of the WT PM level. (b-c) 
Second site suppressor mutations differentially enhance the ∆F508-CFTR rescue by class-
I correctors. The PM density (b) and steady-state expression (c) of ∆F508-CFTR variants 
were determined by ELISA (means ± SEM, n=8) and Western blotting with anti-HA Ab, 
respectively. The PM density data were also plotted in Fig.1e (Y-axis). Na+/K+-ATPase 
(ATPase) was used as a loading control. Cells were treated with correctors (10 µM C3, 3 
µM C18 or 3 µM VX809) for 24 h at 37°C. B, immature core-glycosylated; C, mature 
complex-glycosylated form. (d) The maturation efficiency of ∆F508-CFTR measured by 
metabolic pulse-chase experiments shown in Fig.1d was quantified by densitometry 
(mean ± SEM, n=3-4).  
 
Supplementary Figure 3.  Suppressor mutations and correctors efficiently rescue the 
PM expression and function of ∆F508-CFTR in polarized CFBE41o- epithelial cells.  
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(a-d) The consequence of suppressor mutations-induced NBD1 and/or NBD1-MSD2 
interface stabilization on the PM density, complex-glycosylation and function of ∆F508-
CFTR in CFBE41o- cells. The steady-state expression (a), PM density (b, n=12-24) and 
apical Cl- current (c-d, n=3-4) of ∆F508-CFTR-3HA were measured by Western blotting, 
ELISA and short circuit current, respectively. Data represent means ± SEM. CFTR 
expression was induced for 3-4 days with doxycycline as described in Methods. (e) The 
effect of class-I corrector combination with suppressor mutations on the apical chloride 
current. Representative apical Cl- currents obtained in polarized CFBE41o- cells 
expressing the indicated CFTR variants after 24 h pre-treatment with or without correctors 
(3µM C18 or VX-809) at 37°C. The measurements were performed in presence of a 
basolateral to apical chloride gradient and the current was stimulated by consecutive 
addition of 30 nM, 100 nM, 300 nM, 1 µM, 3 µM, 10 µM forskolin and 100 µM genistein 
followed by CFTR inhibition with 20 µM inhibitor 172 (Inh172). The inhibitor-sensitive 
peak current values are plotted in Fig.1f. (f) Cellular expression of ∆F508-CFTR with or 
without suppressor mutation and VX-809 was measured by immunoblotting in CFBE41o- 
cells. Na+/K+-ATPase (ATPase) was used as a loading control. (gf) Augmented PM 
density of ∆F508-R1S (ResR1S) and ∆F508-R1070W CFTR (ResR1070W) by class-I 
corrector in CFBE41o- cells was calculated as in Fig.S2a. The >2 log2 ratio of ResR1S over 
ResR1070W indicates the preferential effect of class-I correctors on the NBD1-MSD2 
interface (right).  
 
Supplementary Figure 4. C18 prevents thermal inactivation of the ∆F508-2RK 
CFTR channel in vitro 
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(a-c) The effect of the 2RK mutation on the ∆F508-CFTR biochemical and functional 
phenotype. (a) The PM density of the CFTR constructs was measured by cell surface 
ELISA in BHK cells. The 2RK mutation modestly improved the ∆F508-CFTR low 
temperature rescue and (b) PM stability. Anti-HA Ab bound BHK cells were incubated 
for the indicated chase time at 37°C and the OM remaining CFTR was measured by 
ELISA. (c) The 2RK mutation modestly increased the functional PM stability of the 
rescued ∆F508 CFTR, determined by iodide efflux assay. (d) Representative gating 
current (∼1 min) of reconstituted ∆F508-CFTR-2RK in artificial phospholipid bilayer in 
the presence of 3 µM C18 during the temperature ramp at ∼24°C, ∼30°C and ∼36°C. 
Open probability (Po) of CFTR was analyzed at the indicated temperature as described in 
Methods and summarized in Fig.2b. Two channels were incorporated into the bilayer for 
the experiment showing the gating activity at 30°C and 36°C. A single channel activity 
from a separate experiment is shown at 24°C.  The channel closed state is indicated by 
“c”.  
 
Supplementary Figure 5. Docking of VX-809 to the ∆F508-NBD1 crystal structure, 
as well as to the closed and open ∆F508 CFTR models.   
(a) In silico docking of VX-809 was performed to the X-ray structure of NBD1 
(PDBID:2BBT) to mimic corrector binding during or immediately after NBD1 translation, 
preceding complete domain-domain assembly. Solubilizing mutations in the 2BBT 
structure were reverted to WT (see details in Methods). In the simulation using this NBD1 
structure, VX-809 is bound to the isolated NBD1 at the CL1/4 or the NBD2 interface. 
Views from three different orientations are presented. The cytosolic loops (CL1 and CL4) 
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are shown for comparison to the full-length CFTR model. Clusters are depicted in mesh 
representation to indicate their volume. Red, blue, magenta, and cyan of VX-809 clusters 
represent increasing binding free energy with the corresponding color number specifying 
the domain binding. The size of individual clusters and their average binding energy can 
be found in Supplementary Table 3. The CFTR binding sites were determined using 
PyMOL (http://www.pymol.org) by selecting amino acids in less than 4 Å distance from 
every molecule in each cluster. (b) For in silico docking to ∆F508 CFTR the search space 
includes NBD1, NBD2 and major parts of CL1-4. The grid box is depicted on the closed 
CFTR model. Color-coding is the same as in panel a and Fig.1a.  (c-f) In silico docking of 
the VX-809 to the closed and open ∆F508 CFTR models. VX-809 primary binding is 
indicated as site I at the CL1/4-NBD1/2 interface in the full-length closed and open 
molecules (c, e, and Fig.2c). We further performed in silico docking of VX-809 to the 
∆F508-CFTR-∆NBD2 model considering that NBD2 is dispensable for the CFTR folding 
and that VX-809 effect was almost completely retained upon ∆NBD2 (Fig.3e-f). In closed 
CFTR-∆NBD2 an additional binding site is predicted at the β-subdomain (site II) (c-d). 
Moreover, the NBD1-CL1/4 interface near the ∆F508 cavity was predicted as the binding 
site in addition to site I and site II in the closed CFTR-∆NBD2 model (d and f). NBD2 is 
hidden in the full-length model to facilitate comparison. Color-coding is the same as in 
Supplementary Fig.5b.   
 
Supplementary Figure 6. The effect of NBD1-CL4 stabilization on the corrector-
induced rescue of CFTR variants in BHK cells.  
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(a) PM density of ∆F508-CFTR-3S, ∆F508- CFTR-3S-R1070W and ∆F508-CFTR-3S-
V510D was measured by cell surface ELISA in BHK cells treated with correctors for 24 h 
at 37°C. The same data are also plotted in Fig.3d as % of the respective DMSO controls. 
(b) The effect of correctors on the PM density of WT CFTR and V510D-CFTR (WT-
V510D) was measured by cell surface ELISA as in panel (a). Correction efficiency was 
normalized for WT (left), and for the respective DMSO control (right). (c) Steady-state 
expression (upper) and PM density (lower) of R170G-CFTR with stabilized NBD1-MSD2 
interface (V510D) or NBD1 (R1S) were examined by Western blotting and cell surface 
ELISA, respectively. (d) The effect of correctors on the PM density of R170G-CFTR and 
R170G-V510D-CFTR was measured by ELISA as in panel b. ELISA data represent 
means ± SEM (n=8). Cells were exposed to correctors (10 µM C3, 3 µM C18, 3 µM 
VX809 or 10 µM C4) for 24 h at 37°C.  
 
Supplementary Figure 7. The effect of correctors on the expression of TM1, CL1 and 
CL2 CFTR mutants, CFTR domain combinations and CFTR-∆NBD2. 
(a) PM density of MSD1 CFTR mutants in the TM1 (G85E, G91R), CL1 (S168/S169A, 
R170G, K174A, Q179K) or CL2 (M265R, W277R) were measured by cell surface ELISA 
in BHK cells treated with 3 µM VX-809 for 24 h at 37°C. (b-e) Effect of VX-809 on the 
steady-state expression of CFTR domain combinations was examined by Western blotting 
with the CFTR N-terminal tail specific MM13-4 or anti-HA Ab. VX-809 was added as in 
panel a. (b) Accumulation of WT and ∆F508 MSD1-NBD1 fragments was increased by 
VX-809. (c-d) VX-809 increased the cellular expression of the WT CFTR domains 
containing MSD1, but not without MSD1. The relative level of the CFTR domains 
52 
quantified by densitometry is indicated. (e) Summary of the VX-809 effect on the 
expression of WT CFTR domain combinations. CFTR domain boundaries are indicated as 
amino acid residues in the primary sequence. M1, MSD1; N1, NBD1; M2, MSD2; N2, 
NBD2. (f-g) Effect of NBD2 deletion (∆NBD2) on the correction of the ∆F508-CFTR-
R1070W PM density (f) and cellular expression (g), measured by ELISA and Western 
blotting, respectively. Cells were exposed to correctors (10 µM C3, 3 µM C18, 3 µM 
VX809, 10 µM C4, 5 µg/ml core-corr-II or 10% glycerol) for 24 h at 37°C (f-g). All 
ELISA data represent means ± SEM (n=6-9). 
 
Supplementary Figure 8.  In silico docking of C4 to the ∆F508-NBD1 crystal 
structure (a), closed (b-c) and open (d-e) ∆F508-CFTR models. In the full-length 
CFTR models, C4 was predicted to bind to site I at the MSD1/2-NBD1/2 interface, site II 
and III at the NBD1-NBD2 interface and near regulatory insertion (site RI) (b and d). C4 
putative binding, however, was diminished at both sites I and RI in the closed CFTR-
∆NBD2 model, as well as at sites II and III in the open CFTR-∆NBD2 model.  C4 
binding, however, was detected at site I in the open CFTR-∆NBD2 model (c and e). 
Considering that the NBD2 was indispensable for the C4 rescue effect (Fig.3e-f and 
Supplementary Fig.7f-g), site II and site III likely represent functionally relevant binding 
sites for the C4. The RI region could be ruled out as a relevant C4 binding site for rescue, 
since deletion of the RI region largely preserved the C4 rescue effect of the ∆F508-CFTR-
∆RI (Supplementary Fig.9f). Color-coding is as defined in Supplementary Fig.5.   
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Supplementary Figure 9. In silico docking of core-corr-II to the ∆F508-NBD1 crystal 
structure, as well as to the closed and open ∆F508-CFTR models.  (a) Core-corr-II, 
similar to VX-809 and C4, is docked to the NBD1 binding cavity of the CL4. (b) In the 
closed CFTR model, core-corr-II binds to sites I, II and RI. (c) These interactions are 
either weakened or disappeared in the absence of NBD2. (d-e) In the open CFTR model, 
core-corr-II binds to site II and partially to site I. (e) Core-corr-II association with site II is 
abolished in the CFTR-∆NBD2 model. Color-coding is as in Supplementary Fig.5. 
According to in silico docking, C4 and core-corr-II are bound to NBD1 at the CL1/4 or 
the NBD2 interface similar to VX-809 (a and Supplementary Fig.8a). However, the 
binding free energies of C4 and core-corr-II were higher than that of VX-809 (-8.4 and -
7.8 compared to -9.9 kcal/mol, respectively; see Supplementary Table 3), consistent with 
the observation that the C4 and core-corr-II rescue efficiency was lower than VX-809. 
Notably, the docking algorithm is sensitive enough on the homology models to yield 
preferential binding to the CL1/4 and not to the symmetrical CL2/3-NBD2 interface 
region and explains, at least in part, the differences in the molecular mechanism of CFTR 
variants rescue by VX-809, C4, and core-corr-II. (f) Class-II correctors binding to the 
Regulatory Insertion (RI) cannot account for the rescue effect since deletion of the RI 
(∆RI) does not diminish the corrector rescue efficiency. The steady-state expression 
(upper panel) and PM density (lower panel) were determined by immunoblotting and 
ELISA, respectively, (n=6-9, ± SEM). Cells were exposed to correctors (10 µM C3, 3 µM 
C18, 3 µM VX809, 10 µM C4, 5 µg/ml core-corr-II or 10% glycerol) for 24 h at 37°C.   
 
Supplementary Figure 10. Effect of correctors on the isolated NBD1 stability in vitro.  
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(a) Melting temperature (Tm) of isolated human ∆F508-NBD1-1S was measured in vitro 
by differential scanning fluorimetry (DSF)26. WT-NBD1-1S was used as a positive 
control. The indicated correctors or chemical chaperones (CC) (see Supplementary Table 
1) were included during thermal unfolding at the following two concentrations:  3 µM and 
10 µM C1, C2, C3, C4, C5, C6, C7, C9, C11, C12, C13, C14, C17, CoPo,  10 µM and 20 
µM C8, C15, C16,  1 µM and 3 µM C18, VX-809,  5 µM and 15 µM RDR1,  2.5 µg/ml 
and 5 µg/ml core-corr-II, 5% and 10% glycerol, 150 mM and 300 mM TMAO, taurine, 
myo-inositol and D-sorbitol. Thermal unfolding scans of ∆F508-NBD1-1S in the presence 
of selected correctors are shown in Fig.4a. Data represent means ± SEM (n=3). 
Statistically significant change in Tm was considered larger than mean ± 3SD of DMSO 
treated ∆F508-NBD1-1S (34.1 ± 1.5°C). The inset indicates the ∆F508-NBD1-1S  Tm 
elevation as a function of increasing ATP concentration. (b) Effect of C11 on the in vitro 
ubiquitination of WT or ∆F508-NBD1-1S by CHIP was analyzed by Western blotting 
with anti-NBD1 (L12B4) antibody as previously26. (c) Representative mass spectra of 
singly charged peptides after 5 min labelling with D2O; 505NIIF508 (NIIF + H+ = 506.30) of 
wt NBD1-1S (left panel) and 505NIIG509 (NIIG + H+ = 416.25) of ∆F508-NBD1-1S (right 
panel) at 22 °C. Theoretical monoisotopic masses of singly charged peptides are shown. 
 
Supplementary Figure 11. ∆F508-CFTR rescue by corrector combination in 
MDCKII and NCI-H441 polarized epithelia.   
(a, b) PM density (a) and steady-state expression (b) of ∆F508-CFTR in MDCKII cells 
were measured by ELISA (n=8) and Western blotting, respectively. Correctors were 
added with or without 5% or 10% glycerol (Gly) at 37°C for 24 h. The same concentration 
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of correctors were used in both panels. Low temperature (26°C) rescued ∆F508-CFTR 
(r∆F) was used as a positive control. (c) PM density of ∆F508-CFTR in NCI-H441 Tet-on 
cells (n=8). Data represent means ± SEM. (d) Corrector combination synergistically 
rescues the ∆F508-CFTR in MDCKII and NCI-H441 Tet-On epithelial cells. PM density 
of cells treated with VX-809 (3 µM) or corrector combination (3 µM VX-809, 10 µM C4 
and 5% glycerol [Gly]) was determined by cell surface ELISA (n=6-16). 
 
Supplementary Figure 12. Effect of correctors on WT CFTR PM expression in BHK 
cells 
(a) PM density of WT CFTR was measured by cell surface ELISA in BHK cells treated 
with correctors (10 µM C3, 10 µM C4, 3 µM C18, 3 µM VX-809 or 10% glycerol) at 
37°C for 24 h. (b) Effect of second-site suppressor mutations on the corrector efficacy on 
WT expression was determined by PM ELISA. Correctors were added as in panel a. Data 
represent means ± SEM (n=8). (c) Comparison of VX-809 in silico docking to WT and 
∆F508 CFTR closed conformation. Docking and analysis was performed as described in 
Methods. The poses of VX-809 with the lowest energies (red) occupy the site I as in the 
case of the ∆F508 CFTR (right; see also Fig.S5c). A low energy cluster (magenta) in the 
WT partially overlaps with two low energy clusters (blue and turquoise) in the ∆F508 
CFTR. At the back of RI and the β-subdomain an additional docking site appears 
(turquoise) in the WT. These results suggest that the targets of VX-809 are partially 
overlap in the WT and ∆F508 CFTR. 
 
 
Supplementary Figure 13. Full size views of autoradiographs and western blot films 
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displayed in cropped formats in Figures 1, 3, 5 and 6, as well as Supplementary Figs. 2 
and 3 as indicated nearby each panel. 
 
